Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2020
(Exact name of registrant as specified in its charter)
 New York
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification Number)
 122 Smith Road, Kinderhook, NY
 (Address of principal executive offices)
 (Zip Code)
Registrant’s telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 Title of each class
 Trading Symbol(s)
 Name of each exchange on which registered
 Over-the-counter-Pink Sheets
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 7, 2020, Diane Generous informed the Board of her decision to resign from her position on the Company’s Board of Directors. Mrs. Generous provided the Company with her resignation in writing and her letter did not contain any statements describing disagreements with the Company related to its operations, policies or practices, not did any such disagreement lead to her resignation. Mrs. Generous has served on the Board of Directors since December 2014. She has served as the Chairman of the Nominating Committee and as a member of the Audit and Compensation Committees.
The remaining members of the Board of Directors, (Chairman Chaim Davis, Jean Neff, Peter Jerome and Company Chief Executive Officer/Principal Financial Officer Melissa Waterhouse) are considering whether to fill the vacant board seat (whose term is set to expire in June 2020) or to fix the number of board seats to four (4) as allowed under the Company’s Amended and Restated Bylaws by a majority of the Board of Directors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 10, 2020
/s/ Melissa A. Waterhouse  
Melissa A. Waterhouse  
Chief Executive Officer (Principal Executive Officer)
Principal Financial Officer

American Bio Medica (PK) (USOTC:ABMC)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more American Bio Medica (PK) Charts.
American Bio Medica (PK) (USOTC:ABMC)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more American Bio Medica (PK) Charts.